Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Signe Schmidt

Showing results (1-10 of 73) with videos related to

Pageof 8
Sort By:
Danish Medical Journal|November 7, 2013
New technologies in the treatment of type 1 diabetesSigne Schmidt
Diabetes Research and Clinical Practice|February 7, 2012
Glucose sensor excludes hypoglycaemia as cause of deathSigne Schmidt, Kirsten Nørgaard
Ugeskrift for Laeger|December 15, 2016
[The field of technologies for diabetes treatment]Kirsten Nørgaard, Signe Schmidt
Journal of Diabetes Science and Technology|May 31, 2014
Bolus calculatorsSigne Schmidt, Kirsten Nørgaard
Diabetes Technology & Therapeutics|September 29, 2012
Sensor-augmented pump therapy at 36 monthsSigne Schmidt, Kirsten Nørgaard
Diabetes/Metabolism Research and Reviews|October 22, 2020
Glucagon for hypoglycaemia treatment in type 1 diabetesAjenthen G Ranjan, Signe Schmidt, Kirsten Nørgaard
Diabetes, Obesity & Metabolism|March 25, 2025
Faster-acting insulin aspart versus insulin aspart for adults with type 1 diabetes treated with non-automated insulin pump and continuous glucose monitoring-A double-blind randomized controlled crossover trialAjenthen G Ranjan, Signe Schmidt, Kirsten Nørgaard
Journal of Diabetes Science and Technology|March 7, 2017
Sensor-Augmented Insulin Pumps and Hypoglycemia Prevention in Type 1 DiabetesIsabelle Steineck, Ajenthen Ranjan, Kirsten Nørgaard, et al.
Diabetes Care|April 27, 2022
Low-Dose Dasiglucagon Versus Oral Glucose for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes: A Phase 2, Randomized, Three-Arm Crossover StudyChristian Laugesen, Ajenthen G Ranjan, Signe Schmidt, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 26, 2019
Preference for Subcutaneously Administered Low-Dose Glucagon Versus Orally Administered Glucose for Treatment of Mild Hypoglycemia: A Prospective Survey StudyRikke Tetzschner, Ajenthen G Ranjan, Signe Schmidt, et al.
Pageof 8

Showing results (1-10 of 73) with videos related to

Sort By:
Pageof 8
Danish Medical Journal|November 7, 2013
New technologies in the treatment of type 1 diabetesSigne Schmidt
Diabetes Research and Clinical Practice|February 7, 2012
Glucose sensor excludes hypoglycaemia as cause of deathSigne Schmidt, Kirsten Nørgaard
Ugeskrift for Laeger|December 15, 2016
[The field of technologies for diabetes treatment]Kirsten Nørgaard, Signe Schmidt
Journal of Diabetes Science and Technology|May 31, 2014
Bolus calculatorsSigne Schmidt, Kirsten Nørgaard
Diabetes Technology & Therapeutics|September 29, 2012
Sensor-augmented pump therapy at 36 monthsSigne Schmidt, Kirsten Nørgaard
Diabetes/Metabolism Research and Reviews|October 22, 2020
Glucagon for hypoglycaemia treatment in type 1 diabetesAjenthen G Ranjan, Signe Schmidt, Kirsten Nørgaard
Diabetes, Obesity & Metabolism|March 25, 2025
Faster-acting insulin aspart versus insulin aspart for adults with type 1 diabetes treated with non-automated insulin pump and continuous glucose monitoring-A double-blind randomized controlled crossover trialAjenthen G Ranjan, Signe Schmidt, Kirsten Nørgaard
Journal of Diabetes Science and Technology|March 7, 2017
Sensor-Augmented Insulin Pumps and Hypoglycemia Prevention in Type 1 DiabetesIsabelle Steineck, Ajenthen Ranjan, Kirsten Nørgaard, et al.
Diabetes Care|April 27, 2022
Low-Dose Dasiglucagon Versus Oral Glucose for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes: A Phase 2, Randomized, Three-Arm Crossover StudyChristian Laugesen, Ajenthen G Ranjan, Signe Schmidt, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 26, 2019
Preference for Subcutaneously Administered Low-Dose Glucagon Versus Orally Administered Glucose for Treatment of Mild Hypoglycemia: A Prospective Survey StudyRikke Tetzschner, Ajenthen G Ranjan, Signe Schmidt, et al.
Pageof 8